- Optimal treatment strategies based on the latest clinical data and guidelines for advanced pancreatic cancer:
- Newly diagnosed patients
- Therapy choices for patients whose disease has progressed after first-line treatment
- Neoadjuvant and adjuvant systemic therapy strategies
- Promising investigational agents and treatment strategies in clinical trials
- Prognostic and predictive biomarkers
- Other promising therapeutic targets
- Strategies to overcome lack of response to single-agent immune checkpoint inhibitors
Kenneth Yu, MD
Gastrointestinal Oncology Service
Memorial Sloan Kettering Cancer Center
Assistant Professor, Weill Cornell Medical College
New York, New York
Adjunct Assistant Professor
Department of Pharmacology
University of Pennsylvania
Cold Spring Harbor Laboratory
Cold Spring Harbor, New York
Gain expert guidance on the latest treatment of newly diagnosed and relapsed/refractory advanced pancreatic cancer in this 1-hour interactive meeting, with an opportunity to discuss your challenging cases with the experts. Afterward, an associated downloadable slideset will be available on the CCO Web site to enhance the information presented at the live meetings.
The goal of this activity is to improve participants’ competence in treating patients with pancreatic cancer.
This program is intended for physicians, registered nurses, pharmacists, and other healthcare providers who care for patients with pancreatic cancer.
- Apply current guidelines and clinical findings to select individualized therapies for patients with newly diagnosed advanced pancreatic cancer
- Plan treatment strategies for patients with advanced pancreatic cancer after progression on first-line systemic therapy based on available data and treatment guidelines
- Discuss the available data and ongoing trials investigating FOLFIRINOX or nab-paclitaxel as neoadjuvant and adjuvant therapy
- Evaluate clinical potential for emerging investigational agents and treatment strategies in advanced pancreatic cancer
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
This educational activity for 1.0 contact hour is provided by Postgraduate Institute for Medicine.
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.
Provider approved by the California Board of Registered Nursing, Provider Number 13485, for 1.0 contact hour.
A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you within 3 weeks.
Pharmacist Continuing Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008162-9999-18-350-L01-P
Type of Activity
Pharmacists have up to 30 days to complete the online evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.